Transthyretin Amyloidosis Treatment Market Size Worth $9.17 Billion By 2030

Transthyretin Amyloidosis Treatment Market Growth & Trends

The global transthyretin amyloidosis treatment market size is expected to reach USD 9.17 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 7.6% from 2022 to 2030. The transthyretin amyloidosis treatment market is mainly driven by the presence of supportive reimbursement programs and the growing African American population. The increasing African American population acted as a catalyst for the industry growth throughout the period owing to the high susceptibility to ATTR amyloidosis. The Val122Ile is the most prevalent mutation worldwide that leads to cardiomyopathy among the population specific to aged 65 years and above. Furthermore, this Val122Ile mutation is present in 3% to 4% of the African American population worldwide.

An increase in research activities for the development of novel diagnostic techniques and multidisciplinary therapeutic approaches is expected to lead to an increased survival rate and a more favorable prognosis of transthyretin amyloidosis. For instance, in November 2019, the Amyloidosis Research Consortium developed a disease-specific patient-reported outcome (PRO) tool to understand and measure the impact of transthyretin amyloidosis from the patient perspective. An introduction of such a tool will boost the research in developing a new target-specific drug by understanding disease complexity and patients’ need, thereby widening the opportunity in the transthyretin amyloidosis treatment market.

Strategic initiatives undertaken by major players such as creating awareness regarding the target conditions such as ATTR and the long-term benefits of available therapies are expected to fuel industry growth. For instance, in 2019, Pfizer, Inc., in collaboration with the World Heart Federation, started the “Heart Hero” campaign. Under this campaign, Pfizer, Inc. provides educational information and resources related to ATTR-CM to patients and physicians. Such campaigns are expected to boost the early diagnosis of the disease and increase the treatment rate over time.

The movement undertaken by key players to provide free-of-cost medicine under their CSR activities is also projected to fuel market growth. For instance, the Pfizer Patient Assistance Program provides Pfizer medicines such as VYNDAMAX free of cost to eligible patients. People diagnosed with amyloidosis can take advantage of such programs by enrolling at the Vandalink platform. Such programs are expected to encourage physicians to prescribe this drug to a patient as drug therapy in transthyretin amyloidosis patients.

 Request a free sample copy or view report summary: Transthyretin Amyloidosis Treatment Market Report

Transthyretin Amyloidosis Treatment Market Report Highlights

• By type, the ATTR-CM accounted for a leading share in 2021 owing to the high prevalence of the disease and the rising geriatric population. The ATTR-PN is expected to exhibit the fastest growth rate throughout the forecast period. The segment growth is attributed to the presence of a strong pipeline

• By therapy, the targeted therapy segment grabbed a dominant share in 2021 owing to the worldwide approval of the therapies and the growing prescription rate for the treatment of ATTR-CM

• By disease type, the hereditary transthyretin amyloidosis segment dominated the market in 2021 owing to growing strategic alliances among various pharmaceutical companies aiming toward drug development along with growing pipeline drugs

• By distribution channel, the hospital pharmacies captured the largest share in 2021 as most of the hospitals are working toward the diagnosis, research, and treatment of transthyretin amyloidosis

• North America region held the largest share in 2021 owing to the increasing novel drug prescription, proper reimbursement policies, and higher treatment rates in the region

• The MEA region is expected to exhibit the fastest growth rate throughout the forecast period. The segment growth is attributed to the increasing incidence of ATTR amyloidosis 

Transthyretin Amyloidosis Treatment Market Segmentation

Grand View Research has segmented the global transthyretin amyloidosis treatment market based on type, therapy, disease type, distribution channel, and region:

Transthyretin Amyloidosis Treatment Type Outlook (Revenue, USD Million, 2018 - 2030)

• ATTR-PN

• ATTR-CM

Transthyretin Amyloidosis Treatment Therapy Outlook (Revenue, USD Million, 2018 - 2030)

• Targeted Therapy

  • Onpattro

  • Inotersen

  • Vyndaqel/Vyndamax

• Supportive Therapy

• Pipeline Therapy

Transthyretin Amyloidosis Treatment Disease Type Outlook (Revenue, USD Million, 2018 - 2030)

• Hereditary Transthyretin Amyloidosis

  • Polyneuropathy

  • Cardiomyopathy

  • Mixed Type

• Wild Type Amyloidosis

Transthyretin Amyloidosis Treatment Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacies

• Specialty Pharmacies

• Retail Pharmacies

• Online Pharmacies

Transthyretin Amyloidosis Treatment Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • Germany

  • U.K.

  • France

  • Italy

  • Spain

  • Russia

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • Singapore

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

List of Key Players of the Transthyretin Amyloidosis Treatment Market

• Pfizer Inc.

• Johnson & Johnson Services, Inc.

• Ionis Pharmaceuticals, Inc.

• Alnylam Pharmaceuticals, Inc.

• BridgeBio Pharma, Inc.

• Bristol-Myers Squibb Company

• Acrotech Biopharma

• AstraZeneca

• Astellas Pharma, Inc.

• Prothena

• SOM Biotech